SSY Group's subsidiary has signed a letter of intent to license OPT101, a novel non-glucose osmotic agent for peritoneal dialysis, from Switzerland-based Opterion Health AG. The deal sees the Chinese IV infusion manufacturer moving into clinically differentiated renal therapeutics at the earliest possible stage of human data. The LOI covers exclusive rights for mainland China through 2038, with a formal agreement contingent on Phase I data expected in Q3 2026. No financial terms were disclosed.
SSY Group Limited (HKEX: 02005), through its wholly-owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd., signed the LOI on 12 June 2026. Opterion Health AG, founded in 2012 and based in Muttenz, Switzerland, is a privately held, single-asset clinical-stage company focused on peritoneal dialysis. The exclusive license covers patents, technical know-how, and platform technologies pertaining to OPT101 for research, development, manufacturing, and sales in mainland China (excluding Hong Kong, Macao, and Taiwan) through 2038. Shijiazhuang No. 4 also holds priority rights to obtain a license for Hong Kong, Taiwan, and Russia under the same terms. Financial terms — including upfront payment, milestones, and royalties — were not disclosed and are expected to be defined in the formal agreement.
Deal context
OPT101 is described by Opterion as a novel small-molecule osmotic agent designed to replace glucose in peritoneal dialysis (PD) solution. Glucose-based dialysate, the current standard of care, is associated with metabolic complications including peritoneal membrane damage and systemic glycemic disturbance. OPT101 is intended to generate the osmotic pressure needed to remove fluid from the peritoneal cavity without these drawbacks. Opterion submitted a Clinical Trial Application to the European Medicines Agency in September 2025, with the first patient enrolled in the Phase I SPARC trial in February 2026 — approximately four months before the LOI was signed. The only commercially approved non-glucose osmotic agent for PD is icodextrin (Extraneal, Baxter), a glucose polymer that has held that position for decades; no new osmotic agent has achieved regulatory approval since.
The LOI is structured as a non-binding letter of intent with a three-month validity from 12 June 2026, expiring around 12 September 2026 — a window that directly aligns with the expected availability of initial Phase I data. A Priority Cooperation Right gives Shijiazhuang No. 4 the right to match any third-party terms before Opterion can engage external partners, expiring 30 September 2026 and extendable if Phase I data are delayed.